Omada’s GLP-1 Care Track Yields 6.0% Weight Loss and Doubles Fat Reduction
In a 12-week study of 245 adults with obesity, Omada’s GLP-1 Care Track members lost 6.0% of starting weight (1.8× controls’ 3.3%) and cut body fat by 3.3%, twice the control reduction. They also achieved nearly threefold greater muscle mass gains and reported improvements in mental health and physical functioning.
1. Study Design and Participants
The 12-week trial enrolled 245 adults with obesity (BMI ≥ 30), including 151 Omada GLP-1 Care Track members and 94 controls, all of whom had recently started a GLP-1 for weight management. Both groups used at-home scales to track weight and body composition and completed surveys on emotional health and physical function.
2. Weight Loss Outcomes
Omada members lost an average of 6.0% of their starting weight—1.8 times the controls’ 3.3% reduction—demonstrating the program’s impact on accelerating total weight loss beyond GLP-1 medication alone.
3. Body Composition and Well-Being
Participants in Omada’s program reduced body fat by 3.3%, twice the control group’s reduction, and achieved nearly threefold greater muscle mass gains. They also reported superior improvements in mental health, physical functioning and confidence in their weight-loss efforts.
4. Implications for Employers and Health Plans
These results suggest that pairing GLP-1 therapy with Omada’s structured Care Track can enhance both total and high-quality weight loss, offering employers and health plans improved long-term clinical outcomes and stronger return on investment.